Dr. Jay Carpenter, D.O.
What this data tells you about Dr. Carpenter
Dr. Jay Carpenter is an urology physician in Paris, TX, with 12 years in practice. Based on federal Medicare data, Dr. Carpenter performed 15,879 Medicare services across 4,586 unique beneficiaries.
Between the years covered by Open Payments, Dr. Carpenter received a total of $10,834 from 36 pharmaceutical and/or device companies across 216 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Carpenter is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Infectious disease DNA/RNA test | 6,487 | $34 | $88 |
| Yeast/candida DNA test | 2,486 | $34 | $88 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 1,494 | $69 | $175 |
| Automated urinalysis | 1,001 | $2 | $16 |
| Bladder ultrasound after voiding | 632 | $8 | $26 |
| Office visit, established patient (30-39 min) | 593 | $89 | $311 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 497 | $34 | $88 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 497 | $34 | $88 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 497 | $34 | $88 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 497 | $34 | $88 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 497 | $34 | $88 |
| New patient office visit (45-59 min) | 216 | $114 | $405 |
| Office visit, established patient (20-29 min) | 194 | $63 | $220 |
| Diagnostic exam of bladder and urethra using an endoscope | 73 | $175 | $583 |
| Office visit, established patient (10-19 min) | 66 | $35 | $137 |
| New patient office visit (30-44 min) | 32 | $76 | $272 |
| Initial hospital admission, moderate complexity | 30 | $96 | $318 |
| Imaging of urinary tract following injection of a contrast agent | 22 | $19 | $60 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 20 | $319 | $1,017 |
| Chronic care management, first 20 min/month | 19 | $49 | $154 |
| Insertion of stent in ureter using an endoscope | 16 | $80 | $373 |
| Hospital follow-up visit, high complexity | 13 | $91 | $291 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Carpenter is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and high industry engagement (low-engagement, top 19%).
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Carpenter experienced with infectious disease dna/rna test?
Does Dr. Carpenter receive payments from pharmaceutical companies?
How do Dr. Carpenter's costs compare to other urology physicians in Paris?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology